AB0705 Fatigue, Pain and Patient Global Assessment Are Unstable in Spondyloarthropathy Patients with Stable Disease According To Basdai

BackgroundThe use of patient-reported outcome measures has become routine in clinical practice and in clinical trials. In order to use a specific outcome measure in the daily clinic, the natural variation of the outcome measure must be known. Natural variation may also be characterized as measuremen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.1145
Hauptverfasser: Egsmose, E., Madsen, O.R.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Suppl 2
container_start_page 1145
container_title Annals of the rheumatic diseases
container_volume 75
creator Egsmose, E.
Madsen, O.R.
description BackgroundThe use of patient-reported outcome measures has become routine in clinical practice and in clinical trials. In order to use a specific outcome measure in the daily clinic, the natural variation of the outcome measure must be known. Natural variation may also be characterized as measurement error and is assessed in individuals who are considered to be in “steady state”.ObjectivesTo examine natural variation of BASFI, patient global assessment (PaGl), pain, fatigue in patients with stable spondyloarthropathy (SpA).Methods107 SpA patients treated in the daily clinic with a TNF-inhibitor and characterized by stable disease were identified in the Danish rheumatology registry (DANBIO). According to ASAS response criteria for biological treatment in SpA [1] and to previous reports on BASDAI measurement errors [2], stable disease was defined as a change in BASDAI ≤20 between two consecutive visits. Paired data from a single set of such two visits were extracted for each patient. Data comprised BASDAI, BASFI, PaGl, pain and fatigue scored on 0–100 VAS scales. Natural variation was examined using the Bland-Altman method with calculations of lower and upper 95% limits of agreement (LLoA;ULoA) between two consecutive assessments and the corresponding bias (mean of individual differences). Associations between intra-individual inter-visit differences (Δ) were described by linear correlation (r) and stepwise multiple regression analyses (partial regression coefficients (rp) and standard errors of estimation (SEE)).ResultsMean age was 44±14 years, mean inter-visit time duration 16±13 weeks (range 3 – 91) and mean ΔBASDAI 0.0±10.5 (range -20 – 20, ns). Biases were close to 0 for all the variables indicating stable conditions on the group level between the two consecutive visits. On the individual level, differences were more pronounced (Table). LoA for BASFI corresponded to the predefined accepted limits for BASDAI (±20). However, LoA for fatigue, pain and PaGl approximated ±35. No significant correlations were found between the absolute Δvalues of BASDAI, BASFI, fatigue, pain or PaGl and the inter-visit time duration (r range -0.1 – 0.2, ns). ΔBASFI, Δfatigue, Δpain and ΔPaGl were weakly correlated with ΔBASDAI (r range 0.30 – 0.60, p
doi_str_mv 10.1136/annrheumdis-2016-eular.4250
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_1901813513</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322509119</sourcerecordid><originalsourceid>FETCH-LOGICAL-b753-83e8253f1139553cf0c0f06dfc3bed9fcf975f5f68fa89c87cdd23af4d9d01003</originalsourceid><addsrcrecordid>eNpNkE9LwzAUwIMoOKffIbCr1aRp2vTYTTeFgcLmOaRNsma0aU1aZDcvHvyafhJbp-Dp_eH33uP9AJhhdIMxiW-Fta5UfS2ND0KE40D1lXA3UUjRCZjgKGZDO0anYIIQIkGUxsk5uPB-P5SIYTYBn9kcJYh-vX8sRWd2vbqGz8JYKKwcks4o28FV1eSigpn3yvt67GROwRfrO5FXCg70pm2sPFSNcF3pmlZ05eFv2sM305Vwc2TvjFfCK5gVReOksTu4beBceCnMJTjTovLq6jdOwXZ5v108BOun1eMiWwd5QknAiGIhJXp4P6WUFBoVSKNY6oLkSqa60GlCNdUx04KlBUsKKUMidCRTifAgYQpmx7Wta1575Tu-b3pnh4scpwgzTCgmAxUfqbze89aZWrgDx4iP1vk_63y0zn-s89E6-QZHD312</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901813513</pqid></control><display><type>article</type><title>AB0705 Fatigue, Pain and Patient Global Assessment Are Unstable in Spondyloarthropathy Patients with Stable Disease According To Basdai</title><source>BMJ Journals - NESLi2</source><creator>Egsmose, E. ; Madsen, O.R.</creator><creatorcontrib>Egsmose, E. ; Madsen, O.R.</creatorcontrib><description>BackgroundThe use of patient-reported outcome measures has become routine in clinical practice and in clinical trials. In order to use a specific outcome measure in the daily clinic, the natural variation of the outcome measure must be known. Natural variation may also be characterized as measurement error and is assessed in individuals who are considered to be in “steady state”.ObjectivesTo examine natural variation of BASFI, patient global assessment (PaGl), pain, fatigue in patients with stable spondyloarthropathy (SpA).Methods107 SpA patients treated in the daily clinic with a TNF-inhibitor and characterized by stable disease were identified in the Danish rheumatology registry (DANBIO). According to ASAS response criteria for biological treatment in SpA [1] and to previous reports on BASDAI measurement errors [2], stable disease was defined as a change in BASDAI ≤20 between two consecutive visits. Paired data from a single set of such two visits were extracted for each patient. Data comprised BASDAI, BASFI, PaGl, pain and fatigue scored on 0–100 VAS scales. Natural variation was examined using the Bland-Altman method with calculations of lower and upper 95% limits of agreement (LLoA;ULoA) between two consecutive assessments and the corresponding bias (mean of individual differences). Associations between intra-individual inter-visit differences (Δ) were described by linear correlation (r) and stepwise multiple regression analyses (partial regression coefficients (rp) and standard errors of estimation (SEE)).ResultsMean age was 44±14 years, mean inter-visit time duration 16±13 weeks (range 3 – 91) and mean ΔBASDAI 0.0±10.5 (range -20 – 20, ns). Biases were close to 0 for all the variables indicating stable conditions on the group level between the two consecutive visits. On the individual level, differences were more pronounced (Table). LoA for BASFI corresponded to the predefined accepted limits for BASDAI (±20). However, LoA for fatigue, pain and PaGl approximated ±35. No significant correlations were found between the absolute Δvalues of BASDAI, BASFI, fatigue, pain or PaGl and the inter-visit time duration (r range -0.1 – 0.2, ns). ΔBASFI, Δfatigue, Δpain and ΔPaGl were weakly correlated with ΔBASDAI (r range 0.30 – 0.60, p&lt;0.01). In multiple regression analyses, ΔBASFI was best predicted by Δpain, and Δfatigue, Δpain and ΔPaGl by ΔBASDAI (rp range 0.40 – 0.49, p&lt;0.0001, SEE). Although the associations were highly significant, SEEs were high (range 10.8 – 15.6) illustrating poor agreement in individuals.Table 1.Agreements between two consecutive measurements in SpA patients with stable disease (change in BASDAI ≤20)LevelGroup (mean ± SD)IndividualVisit 1Visit 2BiasLLoAULoABASFI33.0±24.832.7±25.2−0.3±11.7 (ns)−23.2+22.6Fatigue49.3±28.248.7±28.7−0.6±18.8 (ns)−37.4+36.2Pain35.6±26.934.8±25.7−0.8±17.0 (ns)−34.1+32.5PaGl40.8±27.939.4±27.9−1.4±17.5 (ns)−35.7+32.9ConclusionsIndependently of time duration, fatigue, pain and PaGl fluctuated substantially and unpredictable in SpA patients with stable BASDAI. In the daily clinic, a change in these outcome measures of at least 35 may be considered as natural variation or “measurement error” with no clinically important relation to the disease activity.ReferencesBraun J et al. Ann Rheum Dis 2003; 62: 817–24.Madsen OR et al. Clin Rheumatol 2010; 29: 849–54.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.4250</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1145</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/75/Suppl_2/1145.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/75/Suppl_2/1145.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,23571,27924,27925,77600,77631</link.rule.ids></links><search><creatorcontrib>Egsmose, E.</creatorcontrib><creatorcontrib>Madsen, O.R.</creatorcontrib><title>AB0705 Fatigue, Pain and Patient Global Assessment Are Unstable in Spondyloarthropathy Patients with Stable Disease According To Basdai</title><title>Annals of the rheumatic diseases</title><description>BackgroundThe use of patient-reported outcome measures has become routine in clinical practice and in clinical trials. In order to use a specific outcome measure in the daily clinic, the natural variation of the outcome measure must be known. Natural variation may also be characterized as measurement error and is assessed in individuals who are considered to be in “steady state”.ObjectivesTo examine natural variation of BASFI, patient global assessment (PaGl), pain, fatigue in patients with stable spondyloarthropathy (SpA).Methods107 SpA patients treated in the daily clinic with a TNF-inhibitor and characterized by stable disease were identified in the Danish rheumatology registry (DANBIO). According to ASAS response criteria for biological treatment in SpA [1] and to previous reports on BASDAI measurement errors [2], stable disease was defined as a change in BASDAI ≤20 between two consecutive visits. Paired data from a single set of such two visits were extracted for each patient. Data comprised BASDAI, BASFI, PaGl, pain and fatigue scored on 0–100 VAS scales. Natural variation was examined using the Bland-Altman method with calculations of lower and upper 95% limits of agreement (LLoA;ULoA) between two consecutive assessments and the corresponding bias (mean of individual differences). Associations between intra-individual inter-visit differences (Δ) were described by linear correlation (r) and stepwise multiple regression analyses (partial regression coefficients (rp) and standard errors of estimation (SEE)).ResultsMean age was 44±14 years, mean inter-visit time duration 16±13 weeks (range 3 – 91) and mean ΔBASDAI 0.0±10.5 (range -20 – 20, ns). Biases were close to 0 for all the variables indicating stable conditions on the group level between the two consecutive visits. On the individual level, differences were more pronounced (Table). LoA for BASFI corresponded to the predefined accepted limits for BASDAI (±20). However, LoA for fatigue, pain and PaGl approximated ±35. No significant correlations were found between the absolute Δvalues of BASDAI, BASFI, fatigue, pain or PaGl and the inter-visit time duration (r range -0.1 – 0.2, ns). ΔBASFI, Δfatigue, Δpain and ΔPaGl were weakly correlated with ΔBASDAI (r range 0.30 – 0.60, p&lt;0.01). In multiple regression analyses, ΔBASFI was best predicted by Δpain, and Δfatigue, Δpain and ΔPaGl by ΔBASDAI (rp range 0.40 – 0.49, p&lt;0.0001, SEE). Although the associations were highly significant, SEEs were high (range 10.8 – 15.6) illustrating poor agreement in individuals.Table 1.Agreements between two consecutive measurements in SpA patients with stable disease (change in BASDAI ≤20)LevelGroup (mean ± SD)IndividualVisit 1Visit 2BiasLLoAULoABASFI33.0±24.832.7±25.2−0.3±11.7 (ns)−23.2+22.6Fatigue49.3±28.248.7±28.7−0.6±18.8 (ns)−37.4+36.2Pain35.6±26.934.8±25.7−0.8±17.0 (ns)−34.1+32.5PaGl40.8±27.939.4±27.9−1.4±17.5 (ns)−35.7+32.9ConclusionsIndependently of time duration, fatigue, pain and PaGl fluctuated substantially and unpredictable in SpA patients with stable BASDAI. In the daily clinic, a change in these outcome measures of at least 35 may be considered as natural variation or “measurement error” with no clinically important relation to the disease activity.ReferencesBraun J et al. Ann Rheum Dis 2003; 62: 817–24.Madsen OR et al. Clin Rheumatol 2010; 29: 849–54.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpNkE9LwzAUwIMoOKffIbCr1aRp2vTYTTeFgcLmOaRNsma0aU1aZDcvHvyafhJbp-Dp_eH33uP9AJhhdIMxiW-Fta5UfS2ND0KE40D1lXA3UUjRCZjgKGZDO0anYIIQIkGUxsk5uPB-P5SIYTYBn9kcJYh-vX8sRWd2vbqGz8JYKKwcks4o28FV1eSigpn3yvt67GROwRfrO5FXCg70pm2sPFSNcF3pmlZ05eFv2sM305Vwc2TvjFfCK5gVReOksTu4beBceCnMJTjTovLq6jdOwXZ5v108BOun1eMiWwd5QknAiGIhJXp4P6WUFBoVSKNY6oLkSqa60GlCNdUx04KlBUsKKUMidCRTifAgYQpmx7Wta1575Tu-b3pnh4scpwgzTCgmAxUfqbze89aZWrgDx4iP1vk_63y0zn-s89E6-QZHD312</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Egsmose, E.</creator><creator>Madsen, O.R.</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>AB0705 Fatigue, Pain and Patient Global Assessment Are Unstable in Spondyloarthropathy Patients with Stable Disease According To Basdai</title><author>Egsmose, E. ; Madsen, O.R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b753-83e8253f1139553cf0c0f06dfc3bed9fcf975f5f68fa89c87cdd23af4d9d01003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Egsmose, E.</creatorcontrib><creatorcontrib>Madsen, O.R.</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Egsmose, E.</au><au>Madsen, O.R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0705 Fatigue, Pain and Patient Global Assessment Are Unstable in Spondyloarthropathy Patients with Stable Disease According To Basdai</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>1145</spage><pages>1145-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundThe use of patient-reported outcome measures has become routine in clinical practice and in clinical trials. In order to use a specific outcome measure in the daily clinic, the natural variation of the outcome measure must be known. Natural variation may also be characterized as measurement error and is assessed in individuals who are considered to be in “steady state”.ObjectivesTo examine natural variation of BASFI, patient global assessment (PaGl), pain, fatigue in patients with stable spondyloarthropathy (SpA).Methods107 SpA patients treated in the daily clinic with a TNF-inhibitor and characterized by stable disease were identified in the Danish rheumatology registry (DANBIO). According to ASAS response criteria for biological treatment in SpA [1] and to previous reports on BASDAI measurement errors [2], stable disease was defined as a change in BASDAI ≤20 between two consecutive visits. Paired data from a single set of such two visits were extracted for each patient. Data comprised BASDAI, BASFI, PaGl, pain and fatigue scored on 0–100 VAS scales. Natural variation was examined using the Bland-Altman method with calculations of lower and upper 95% limits of agreement (LLoA;ULoA) between two consecutive assessments and the corresponding bias (mean of individual differences). Associations between intra-individual inter-visit differences (Δ) were described by linear correlation (r) and stepwise multiple regression analyses (partial regression coefficients (rp) and standard errors of estimation (SEE)).ResultsMean age was 44±14 years, mean inter-visit time duration 16±13 weeks (range 3 – 91) and mean ΔBASDAI 0.0±10.5 (range -20 – 20, ns). Biases were close to 0 for all the variables indicating stable conditions on the group level between the two consecutive visits. On the individual level, differences were more pronounced (Table). LoA for BASFI corresponded to the predefined accepted limits for BASDAI (±20). However, LoA for fatigue, pain and PaGl approximated ±35. No significant correlations were found between the absolute Δvalues of BASDAI, BASFI, fatigue, pain or PaGl and the inter-visit time duration (r range -0.1 – 0.2, ns). ΔBASFI, Δfatigue, Δpain and ΔPaGl were weakly correlated with ΔBASDAI (r range 0.30 – 0.60, p&lt;0.01). In multiple regression analyses, ΔBASFI was best predicted by Δpain, and Δfatigue, Δpain and ΔPaGl by ΔBASDAI (rp range 0.40 – 0.49, p&lt;0.0001, SEE). Although the associations were highly significant, SEEs were high (range 10.8 – 15.6) illustrating poor agreement in individuals.Table 1.Agreements between two consecutive measurements in SpA patients with stable disease (change in BASDAI ≤20)LevelGroup (mean ± SD)IndividualVisit 1Visit 2BiasLLoAULoABASFI33.0±24.832.7±25.2−0.3±11.7 (ns)−23.2+22.6Fatigue49.3±28.248.7±28.7−0.6±18.8 (ns)−37.4+36.2Pain35.6±26.934.8±25.7−0.8±17.0 (ns)−34.1+32.5PaGl40.8±27.939.4±27.9−1.4±17.5 (ns)−35.7+32.9ConclusionsIndependently of time duration, fatigue, pain and PaGl fluctuated substantially and unpredictable in SpA patients with stable BASDAI. In the daily clinic, a change in these outcome measures of at least 35 may be considered as natural variation or “measurement error” with no clinically important relation to the disease activity.ReferencesBraun J et al. Ann Rheum Dis 2003; 62: 817–24.Madsen OR et al. Clin Rheumatol 2010; 29: 849–54.Disclosure of InterestNone declared</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2016-eular.4250</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1145
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901813513
source BMJ Journals - NESLi2
title AB0705 Fatigue, Pain and Patient Global Assessment Are Unstable in Spondyloarthropathy Patients with Stable Disease According To Basdai
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T20%3A23%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0705%E2%80%85Fatigue,%20Pain%20and%20Patient%20Global%20Assessment%20Are%20Unstable%20in%20Spondyloarthropathy%20Patients%20with%20Stable%20Disease%20According%20To%20Basdai&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Egsmose,%20E.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=1145&rft.pages=1145-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.4250&rft_dat=%3Cproquest_bmj_p%3E4322509119%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901813513&rft_id=info:pmid/&rfr_iscdi=true